For the quarter ended June 2025, Royalty Pharma (RPRX Quick QuoteRPRX - Free Report) reported revenue of $727 million, up 19.6% over the same period last year. EPS came in at $1.14, compared to $0.96 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $686.22 million, representing a surprise of +5.94%. The company delivered an EPS surprise of +3.64%, with the consensus EPS estimate being $1.10.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise: $194 million versus the two-analyst average estimate of $206.12 million. The reported number represents a year-over-year change of -0.4%.
• Portfolio Receipts- Royalty Receipts- Products- Tysabri: $56 million versus $53.9 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -12.3% change.
• Portfolio Receipts- Royalty Receipts- Products- Imbruvica: $44 million versus $39.81 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -10.4% change.
• Portfolio Receipts- Royalty Receipts- Products- Xtandi: $42 million versus $42.75 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.8% change.
• Portfolio Receipts- Royalty Receipts- Products- Promacta: $33 million compared to the $39.51 million average estimate based on two analysts. The reported number represents a change of +8.2% year over year.
• Portfolio Receipts- Royalty Receipts- Products- Spinraza: $12 million versus the two-analyst average estimate of $11.66 million.
• Portfolio Receipts- Royalty Receipts- Products- Cabometyx/Cometriq: $20 million versus the two-analyst average estimate of $19.64 million. The reported number represents a year-over-year change of +19.5%.
• Portfolio Receipts- Royalty Receipts- Products- Evrysdi: $33 million versus $31.21 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +32.4% change.
• Portfolio Receipts- Royalty Receipts- Products- Trodelvy: $10 million versus $10.87 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -3.7% change.
• Portfolio Receipts- Royalty Receipts- Products- Total: $672 million compared to the $680.22 million average estimate based on two analysts.
• Portfolio Receipts- Royalty Receipts- Products- Trelegy: $57 million versus the two-analyst average estimate of $57.04 million. The reported number represents a year-over-year change of +17.6%.
• Portfolio Receipts- Royalty Receipts- Products- Tremfya: $37 million compared to the $38.47 million average estimate based on two analysts. The reported number represents a change of +23.7% year over year.

View all Key Company Metrics for Royalty Pharma here>>>

Shares of Royalty Pharma have returned +6.8% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.